HIPAA Compliance Guide for Medication for Opioid Use Disorder (MOUD) Clinics: Requirements and Best Practices

HIPAA Privacy Rule in MOUD Clinics

The HIPAA Privacy Rule governs how your clinic uses and discloses protected health information (PHI) related to diagnosis, medications, dosing, toxicology, and care coordination. Apply the minimum necessary standard to routine operations, and issue a clear Notice of Privacy Practices that explains patient rights and your lawful uses for treatment, payment, and health care operations.

Because MOUD data are highly sensitive, align HIPAA with 42 CFR Part 2 by segmenting substance use disorder information and obtaining patient authorization before sharing when Part 2 applies. Use precise, time-limited authorizations that specify the recipient, purpose, and scope, and honor revocations promptly. When responding to Federal and State Reporting Requirements, verify whether a HIPAA or Part 2 exception truly permits disclosure, and document the legal basis for each release.

• Execute Business Associate Agreements for all vendors that handle PHI.
• Honor patient rights: access, amendments, restrictions, confidential communications, and an accounting of disclosures.
• Maintain a disclosure log that distinguishes HIPAA-permitted releases from those requiring Patient Authorization under 42 CFR Part 2.

HIPAA Security Rule Safeguards

Conduct a formal risk analysis, then implement administrative, physical, and technical safeguards tailored to ePHI in MOUD workflows. Name security and privacy officers, train staff, and maintain policies for device use, email, texting, telehealth, and e-prescribing.

• Access control: role-based permissions, unique IDs, and multi-factor authentication; promptly remove access when roles change.
• Encryption: protect ePHI at rest and in transit; harden mobile devices with passcodes, auto-lock, and remote wipe.
• Audit and integrity: enable audit logs, monitor for anomalous access, patch systems, and use endpoint protection.
• Business continuity: back up ePHI, test restores, and document disaster recovery and downtime procedures.
• Incident response: define triage, containment, forensics, notification, and post-incident review steps; rehearse with tabletop exercises.

Confidentiality of Substance Use Disorder Records

42 CFR Part 2 adds strict confidentiality protections for federally assisted substance use disorder programs, including many MOUD settings. It generally requires written Patient Authorization before disclosing SUD-identifying information, with narrow exceptions (for example, medical emergencies, qualified audits/evaluations, certain research, or a proper court order).

Prohibit redisclosure by attaching the Part 2 notice to every permitted disclosure, and use Qualified Service Organization Agreements when vendors support your Part 2 program. In integrated care, tag SUD data elements so you can share non-Part 2 information for treatment while withholding Part 2-protected details unless authorization or an exception applies.

• Design separate consent workflows for HIPAA and Part 2.
• Segment records so only staff with a need to know can view SUD data.
• Educate staff on when Federal and State Reporting Requirements are permitted despite Part 2 limits, and how to document the legal pathway.

Recordkeeping and Patient Confidentiality in OTPs

Opioid Treatment Programs (OTPs) must maintain rigorous records to preserve safety, accountability, and privacy. Ensure current SAMHSA Certification and DEA Registration, and align procedures with OTP accreditation standards and state rules.

Maintain complete treatment records: intake assessments, individualized plans, counseling notes, dosing logs, take-home eligibility decisions, inventory and chain-of-custody for controlled substances, toxicology results, adverse events, and medication reconciliation. Safeguard methadone and buprenorphine logs as Part 2-protected where applicable, and restrict access to staff with defined roles.

• Reconcile controlled substance inventories daily; investigate and document discrepancies; report losses or thefts per Federal and State Reporting Requirements.
• Use unique patient identifiers on dosing lines to minimize incidental disclosures in clinic areas.
• Retain records for required periods and respond to subpoenas only with proper authorization or court order that meets Part 2 standards.

Telemedicine Prescribing Requirements

When treating via telehealth, verify patient identity and physical location, confirm your licensure for that location, and document informed consent for telemedicine. Use an Interactive Telecommunications System that supports real-time, two-way audio-visual communication when required, and confirm whether audio-only encounters are permitted for the specific service and jurisdiction.

For Controlled Substances Prescribing, follow a thorough medical evaluation, check the PDMP as required, and use Electronic Prescribing of Controlled Substances with two-factor authentication. Confirm that your DEA Registration and any state-level registrations cover the patient’s treatment location. Because federal and state telemedicine rules evolve, verify current requirements before issuing controlled prescriptions and record the compliance basis in the chart.

• Note patient location, emergency contacts, and a contingency plan for urgent needs during the session.
• Use secure, HIPAA-compliant platforms with Business Associate Agreements and protect session recordings or prohibit them per policy.
• Coordinate with pharmacies in advance to ensure timely, confidential dispensing and to clarify any Part 2 consent needs.

Buprenorphine Dispensing Protocols

Establish standardized protocols that cover evaluation, induction, stabilization, and maintenance while preserving confidentiality. Confirm OUD diagnosis, review medical history and co-medications, counsel on risks (for example, with benzodiazepines or alcohol), and co-prescribe naloxone when clinically appropriate. Provide safe-storage education and diversion-mitigation steps.

Offer in-clinic or home induction with clear instructions to avoid precipitated withdrawal; consider micro-induction strategies when recent high-potency opioid exposure is likely. Monitor response, adjust dosing based on cravings and withdrawal, and schedule early follow-ups to reinforce adherence. Use PDMP reviews, urine or oral fluid testing where appropriate, and document all clinical decisions and patient education.

• Use EPCS to transmit buprenorphine prescriptions; verify pharmacy readiness and any prior authorization requirements.
• If dispensing on-site (for example, within an OTP), maintain dosing logs, inventory controls, and secure storage that meet DEA and state standards.
• Obtain Patient Authorization before sharing Part 2-protected details with outside pharmacies or caregivers unless an exception applies.

Training and Regulatory Updates for Prescribers

Maintain current training across privacy, security, and clinical domains. Provide annual HIPAA Privacy and Security refreshers, targeted 42 CFR Part 2 training (including redisclosure prohibitions and Qualified Service Organization Agreements), and scenario-based exercises for telehealth and EPCS workflows.

Ensure prescribers meet substance use disorder education requirements tied to DEA Registration and state licensure, and retain certificates for audits. Track Federal and State Reporting Requirements (for example, PDMP mandates, loss/theft reporting, and OTP-specific rules), and update policies and patient-facing materials as regulations evolve.

Conclusion

By aligning HIPAA’s Privacy and Security Rules with 42 CFR Part 2, sustaining OTP-grade recordkeeping, validating telemedicine criteria, standardizing buprenorphine protocols, and maintaining continuous training, your MOUD clinic can protect patients, meet regulatory expectations, and deliver high-quality, confidential care.

FAQs

What are HIPAA requirements for MOUD clinics?

Apply the minimum necessary standard, provide a Notice of Privacy Practices, execute Business Associate Agreements, and honor patient rights to access, amendments, restrictions, confidential communications, and an accounting of disclosures. Implement Security Rule safeguards—risk analysis, access controls, encryption, auditing, training, backups, and incident response—to protect ePHI across in-person and telehealth care.

How does 42 CFR Part 2 protect substance use disorder records?

42 CFR Part 2 requires written Patient Authorization for most disclosures of SUD-identifying information from federally assisted programs, limits redisclosure, and allows only narrow exceptions (for example, medical emergencies, qualified audits/evaluations, certain research, or a qualifying court order). Programs should segment SUD data, attach the required prohibition-on-redisclosure notice, and use Qualified Service Organization Agreements with vendors.

What training is required for buprenorphine prescribers?

Prescribers should complete substance use disorder education associated with DEA Registration and any state CME mandates, maintain documentation of completion, and receive ongoing training in HIPAA, 42 CFR Part 2, telehealth, and EPCS. Clinics should refresh training annually and whenever regulations or internal protocols change.

Can controlled substances be prescribed via telehealth in MOUD treatment?

Yes, when legal and clinical requirements are met. Confirm licensure in the patient’s location, use an Interactive Telecommunications System when required, perform a sufficient evaluation, check the PDMP as applicable, and issue prescriptions via EPCS. Because federal and state telemedicine rules change, verify current standards before prescribing and document the authority relied upon.